1. Anti-infection Autophagy Metabolic Enzyme/Protease
  2. Reverse Transcriptase HIV Autophagy Endogenous Metabolite Parasite
  3. Efavirenz

Efavirenz  (Synonyms: DMP 266; EFV; L-743726)

Cat. No.: HY-10572 Purity: 99.93%
SDS COA Handling Instructions Technical Support

Efavirenz (DMP 266) is a potent inhibitor of the wild-type HIV-1 reverse transcriptase with a Ki of 2.93 nM and exhibits an IC95 of 1.5 nM for the inhibition of HIV-1 replicative spread in cell culture.

For research use only. We do not sell to patients.

Efavirenz Chemical Structure

Efavirenz Chemical Structure

CAS No. : 154598-52-4

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
5 mg In-stock
10 mg In-stock
50 mg In-stock
100 mg   Get quote  
200 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 10 publication(s) in Google Scholar

Other Forms of Efavirenz:

Top Publications Citing Use of Products

    Efavirenz purchased from MedChemExpress. Usage Cited in: Cell Physiol Biochem. 2015;37(6):2496-507.  [Abstract]

    Arithmetic means±SEM (n=19) of erythrocyte annexin-V-binding (black bars) following incubation for 48 hours to Ringer solution without (white bar) or with (black bars) presence of Efavirenz (1-4 µg/mL).

    View All HIV Isoform Specific Products:

    View All Parasite Isoform Specific Products:

    • Biological Activity

    • Protocol

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Efavirenz (DMP 266) is a potent inhibitor of the wild-type HIV-1 reverse transcriptase with a Ki of 2.93 nM and exhibits an IC95 of 1.5 nM for the inhibition of HIV-1 replicative spread in cell culture[1].

    IC50 & Target

    HIV-1

     

    Cellular Effect
    Cell Line Type Value Description References
    C8166 EC50
    0.0027 μM
    Compound: efavirenz
    Antiviral activity against HIV1 3B infected human C8166 cells assessed as inhibition of syncytia formation by p24 antigen based assay
    Antiviral activity against HIV1 3B infected human C8166 cells assessed as inhibition of syncytia formation by p24 antigen based assay
    [PMID: 19170521]
    C8166 EC50
    183.63 μM
    Compound: EFV
    Antiviral activity against HIV1 A17 infected in human C8166 cells assessed as reduction in p24 antigen level incubated for 4 hrs followed by cell plating for 72 hrs by ELISA method
    Antiviral activity against HIV1 A17 infected in human C8166 cells assessed as reduction in p24 antigen level incubated for 4 hrs followed by cell plating for 72 hrs by ELISA method
    [PMID: 27039251]
    CCRF-CEM CC50
    > 100 μM
    Compound: EFV
    Cytotoxicity against HIV1 infected human CEM cells assessed as reduction in cell viability after 7 days by MTT assay
    Cytotoxicity against HIV1 infected human CEM cells assessed as reduction in cell viability after 7 days by MTT assay
    [PMID: 27390064]
    CCRF-CEM EC50
    > 10000 nM
    Compound: EFV
    Antiviral activity against HIV2 isolate ROD infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days by microscopic analysis
    Antiviral activity against HIV2 isolate ROD infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days by microscopic analysis
    [PMID: 21366296]
    CCRF-CEM EC50
    > 10000 nM
    Compound: EFV, DMP-266
    Antiviral activity against HIV2 ROD infected in human CEM cells assessed as protection against virus-induced cytopathicity by giant cell formation assay
    Antiviral activity against HIV2 ROD infected in human CEM cells assessed as protection against virus-induced cytopathicity by giant cell formation assay
    [PMID: 25418038]
    CCRF-CEM EC50
    > 10000 nM
    Compound: EFV, DMP-266
    Antiviral activity against HIV-2 ROD infected in human CEM cells assessed as protection of cells monitored by giant cell formation by microscopy
    Antiviral activity against HIV-2 ROD infected in human CEM cells assessed as protection of cells monitored by giant cell formation by microscopy
    [PMID: 24769348]
    CCRF-CEM CC50
    > 10000 μM
    Compound: EFV
    Cytotoxicity against human CEM cells by coulter counter analysis
    Cytotoxicity against human CEM cells by coulter counter analysis
    [PMID: 21366296]
    CCRF-CEM EC50
    1.5 nM
    Compound: EFV
    Antiviral activity against wild type HIV1 3B infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days by microscopic analysis
    Antiviral activity against wild type HIV1 3B infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days by microscopic analysis
    [PMID: 21366296]
    CCRF-CEM EC50
    1.5 nM
    Compound: EFV, DMP-266
    Antiviral activity against HIV1 3B infected in human CEM cells assessed as protection against virus-induced cytopathicity by giant cell formation assay
    Antiviral activity against HIV1 3B infected in human CEM cells assessed as protection against virus-induced cytopathicity by giant cell formation assay
    [PMID: 25418038]
    CCRF-CEM EC50
    1.5 nM
    Compound: EFV, DMP-266
    Antiviral activity against HIV1 3B infected in human CEM cells assessed as protection of cells monitored by giant cell formation by microscopy
    Antiviral activity against HIV1 3B infected in human CEM cells assessed as protection of cells monitored by giant cell formation by microscopy
    [PMID: 24769348]
    CEM-SS EC50
    0.005 μM
    Compound: efavirenz
    Antiviral activity against HIV1 RF in human CEM-SS cells by XTT assay
    Antiviral activity against HIV1 RF in human CEM-SS cells by XTT assay
    [PMID: 17803290]
    CEM-SS CC50
    0.55 μM
    Compound: Efavirenz
    Cytotoxicity against human CEM-SS cells by MTS assay
    Cytotoxicity against human CEM-SS cells by MTS assay
    10.1039/C4MD00282B
    CEM-SS EC50
    0.92 nM
    Compound: Efavirenz
    Antiviral activity against HIV1 RF infected in CEM-SS cells assessed as inhibition of virus-induced cytopathic effect by MTS assay
    Antiviral activity against HIV1 RF infected in CEM-SS cells assessed as inhibition of virus-induced cytopathic effect by MTS assay
    10.1039/C4MD00282B
    HEK-293T CC50
    > 30 μM
    Compound: Efavirenz
    Cytotoxicity against human HEK 293T cells assessed as reduction in cell viability measured after 48 hrs by Celltiter-glo assay
    Cytotoxicity against human HEK 293T cells assessed as reduction in cell viability measured after 48 hrs by Celltiter-glo assay
    [PMID: 32004936]
    HEK-293T EC50
    0.0005 μM
    Compound: efavirenz
    Antiviral activity against HIV in HEK293T cells after 48 hrs
    Antiviral activity against HIV in HEK293T cells after 48 hrs
    [PMID: 17035019]
    HEK-293T IC50
    0.00084 μM
    Compound: EFV
    Antiviral activity against wild type HIV1 infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay
    Antiviral activity against wild type HIV1 infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay
    [PMID: 25072874]
    HEK-293T IC50
    0.00104 μM
    Compound: EFV
    Antiviral activity against wild-type HIV-1 NL4-3 harboring vesicular stomatitis virus glycoprotein infected in HEK293T cells pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase reporter gene assay
    Antiviral activity against wild-type HIV-1 NL4-3 harboring vesicular stomatitis virus glycoprotein infected in HEK293T cells pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase reporter gene assay
    [PMID: 27484516]
    HEK-293T IC50
    0.00565 μM
    Compound: EFV
    Antiviral activity against HIV1 harboring reverse transcriptase Y181C mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay
    Antiviral activity against HIV1 harboring reverse transcriptase Y181C mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay
    [PMID: 25072874]
    HEK-293T IC50
    0.00565 μM
    Compound: EFV
    Antiviral activity against HIV-1 NL4-3 harboring RT-Y181C mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase reporter gene
    Antiviral activity against HIV-1 NL4-3 harboring RT-Y181C mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase reporter gene
    [PMID: 27484516]
    HEK-293T IC50
    0.056 μM
    Compound: EFV
    Antiviral activity against HIV1 harboring reverse transcriptase K103N/G190A double mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay
    Antiviral activity against HIV1 harboring reverse transcriptase K103N/G190A double mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay
    [PMID: 25072874]
    HEK-293T IC50
    0.056 μM
    Compound: EFV
    Antiviral activity against HIV-1 NL4-3 harboring RT-K103N/G190A double mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase
    Antiviral activity against HIV-1 NL4-3 harboring RT-K103N/G190A double mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase
    [PMID: 27484516]
    HEK-293T IC50
    0.0587 μM
    Compound: EFV
    Antiviral activity against HIV-1 NL4-3 harboring RT-K103N/Y181C double mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase
    Antiviral activity against HIV-1 NL4-3 harboring RT-K103N/Y181C double mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase
    [PMID: 27484516]
    HEK-293T IC50
    0.0588 μM
    Compound: EFV
    Antiviral activity against HIV1 harboring reverse transcriptase K103N mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay
    Antiviral activity against HIV1 harboring reverse transcriptase K103N mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay
    [PMID: 25072874]
    HEK-293T IC50
    0.0588 μM
    Compound: EFV
    Antiviral activity against HIV-1 NL4-3 harboring RT-K103N mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase reporter gene
    Antiviral activity against HIV-1 NL4-3 harboring RT-K103N mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase reporter gene
    [PMID: 27484516]
    HEK-293T IC50
    0.083 μM
    Compound: EFV
    Antiviral activity against HIV1 harboring reverse transcriptase K103N/V108I double mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay
    Antiviral activity against HIV1 harboring reverse transcriptase K103N/V108I double mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay
    [PMID: 25072874]
    HEK-293T IC50
    0.083 μM
    Compound: EFV
    Antiviral activity against HIV-1 NL4-3 harboring RT-K103N/V108I double mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase
    Antiviral activity against HIV-1 NL4-3 harboring RT-K103N/V108I double mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase
    [PMID: 27484516]
    HEK-293T IC50
    0.16 μM
    Compound: EFV
    Antiviral activity against HIV1 harboring reverse transcriptase K103N/P225H double mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay
    Antiviral activity against HIV1 harboring reverse transcriptase K103N/P225H double mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay
    [PMID: 25072874]
    HEK-293T IC50
    0.16 μM
    Compound: EFV
    Antiviral activity against HIV-1 NL4-3 harboring RT-K103N/P225H double mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase
    Antiviral activity against HIV-1 NL4-3 harboring RT-K103N/P225H double mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase
    [PMID: 27484516]
    HEK-293T IC50
    0.48 μM
    Compound: EFV
    Antiviral activity against HIV1 harboring reverse transcriptase Y188L mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay
    Antiviral activity against HIV1 harboring reverse transcriptase Y188L mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay
    [PMID: 25072874]
    HEK-293T IC50
    0.48 μM
    Compound: EFV
    Antiviral activity against HIV-1 NL4-3 harboring RT-Y188L mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase reporter gene
    Antiviral activity against HIV-1 NL4-3 harboring RT-Y188L mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase reporter gene
    [PMID: 27484516]
    HEK-293T CC50
    10 μM
    Compound: efavirenz
    Cytotoxicity against HEK293T cells after 48 hrs
    Cytotoxicity against HEK293T cells after 48 hrs
    [PMID: 17035019]
    HEK-293T IC50
    13.8 μM
    Compound: EFV
    Antiviral activity against HIV-1 NL4-3 harboring RT-K103N/Y188L double mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase
    Antiviral activity against HIV-1 NL4-3 harboring RT-K103N/Y188L double mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase
    [PMID: 27484516]
    HEK-293T IC50
    2.49 μM
    Compound: EFV
    Antiviral activity against HIV1 harboring reverse transcriptase L1001/K103N double mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay
    Antiviral activity against HIV1 harboring reverse transcriptase L1001/K103N double mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay
    [PMID: 25072874]
    HEK-293T IC50
    2.49 μM
    Compound: EFV
    Antiviral activity against HIV-1 NL4-3 harboring RT-L100I/K103N double mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase
    Antiviral activity against HIV-1 NL4-3 harboring RT-L100I/K103N double mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase
    [PMID: 27484516]
    HEK-293T EC50
    889 nM
    Compound: EFV
    Antiviral activity against multidrug-resistant HIV1 695-RT infected in HEK293T cells assessed as inhibition of viral replication after 4 days by beta-galactosidase reporter gene assay
    Antiviral activity against multidrug-resistant HIV1 695-RT infected in HEK293T cells assessed as inhibition of viral replication after 4 days by beta-galactosidase reporter gene assay
    [PMID: 22148316]
    HeLa EC50
    > 0.002 μM
    Compound: EFV
    Antiviral activity against HIV1 bearing HIV1 NL4-3 envelope infected in human HeLa CD4 cells coexpressing LTR/beta-Gal gene assessed as reduction in virus-induced beta-galactosidase reporter gene activity after 72 hrs by single-cycle infection assay
    Antiviral activity against HIV1 bearing HIV1 NL4-3 envelope infected in human HeLa CD4 cells coexpressing LTR/beta-Gal gene assessed as reduction in virus-induced beta-galactosidase reporter gene activity after 72 hrs by single-cycle infection assay
    [PMID: 17646410]
    HeLa EC50
    0.0001 μM
    Compound: Efavirenz
    Antiviral activity against HIV1 infected in human HeLa cells expressing CD4-LTR assessed as inhibition of viral entry-related beta galactosidase expression treated for 2 hrs measured after 48 hrs by MAGI assay
    Antiviral activity against HIV1 infected in human HeLa cells expressing CD4-LTR assessed as inhibition of viral entry-related beta galactosidase expression treated for 2 hrs measured after 48 hrs by MAGI assay
    [PMID: 17967909]
    HeLa EC50
    0.0006 μM
    Compound: EFV
    Antiviral activity against wild type HIV1 infected in human HeLa cells assessed as decrease in viral infection after 72 hrs by beta-galactosidase reporter gene assay
    Antiviral activity against wild type HIV1 infected in human HeLa cells assessed as decrease in viral infection after 72 hrs by beta-galactosidase reporter gene assay
    [PMID: 19805571]
    HeLa EC50
    0.0006 μM
    Compound: EFV
    Antiviral activity against HIV1 harboring capsid I201V mutant protein infected in human HeLa cells assessed as decrease in viral infection after 72 hrs by beta-galactosidase reporter gene assay
    Antiviral activity against HIV1 harboring capsid I201V mutant protein infected in human HeLa cells assessed as decrease in viral infection after 72 hrs by beta-galactosidase reporter gene assay
    [PMID: 19805571]
    HeLa EC50
    0.001 μM
    Compound: EFV
    Antiviral activity against HIV1 NL4-3 infected in human HeLa cells assessed as decrease in single-cycle viral infection after 72 hrs by beta-galactosidase reporter gene assay
    Antiviral activity against HIV1 NL4-3 infected in human HeLa cells assessed as decrease in single-cycle viral infection after 72 hrs by beta-galactosidase reporter gene assay
    [PMID: 19805571]
    HeLa EC50
    0.001 μM
    Compound: EFV
    Antiviral activity against HIV1 harboring spacer peptide A1V mutant protein infected in human HeLa cells assessed as decrease in viral infection after 72 hrs by beta-galactosidase reporter gene assay
    Antiviral activity against HIV1 harboring spacer peptide A1V mutant protein infected in human HeLa cells assessed as decrease in viral infection after 72 hrs by beta-galactosidase reporter gene assay
    [PMID: 19805571]
    HeLa EC50
    0.0011 μM
    Compound: EFV
    Antiviral activity against HIV1 bearing VSV envelope infected in human HeLa CD4 cells coexpressing LTR/beta-Gal gene assessed as reduction in virus-induced beta-galactosidase reporter gene activity after 72 hrs by single-cycle infection assay
    Antiviral activity against HIV1 bearing VSV envelope infected in human HeLa CD4 cells coexpressing LTR/beta-Gal gene assessed as reduction in virus-induced beta-galactosidase reporter gene activity after 72 hrs by single-cycle infection assay
    [PMID: 17646410]
    HeLa IC50
    0.4 nM
    Compound: efavirenz, EFV
    Antiviral activity against wild type HIV1 in HeLa cells by MAGI assay
    Antiviral activity against wild type HIV1 in HeLa cells by MAGI assay
    [PMID: 18665583]
    HeLa IC50
    0.6 nM
    Compound: efavirenz, EFV
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase P236L mutant in HeLa cells by MAGI assay
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase P236L mutant in HeLa cells by MAGI assay
    [PMID: 18665583]
    HeLa IC50
    0.8 nM
    Compound: efavirenz, EFV
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase Y181C mutant in HeLa cells by MAGI assay
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase Y181C mutant in HeLa cells by MAGI assay
    [PMID: 18665583]
    HeLa IC50
    0.8 nM
    Compound: efavirenz, EFV
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V106A mutant in HeLa cells by MAGI assay
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V106A mutant in HeLa cells by MAGI assay
    [PMID: 18665583]
    HeLa IC50
    0.9 nM
    Compound: efavirenz, EFV
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V106I mutant in HeLa cells by MAGI assay
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V106I mutant in HeLa cells by MAGI assay
    [PMID: 18665583]
    HeLa IC50
    1 nM
    Compound: efavirenz, EFV
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase G190E mutant in HeLa cells by MAGI assay
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase G190E mutant in HeLa cells by MAGI assay
    [PMID: 18665583]
    HeLa IC50
    1.2 nM
    Compound: efavirenz, EFV
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase E138K mutant in HeLa cells by MAGI assay
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase E138K mutant in HeLa cells by MAGI assay
    [PMID: 18665583]
    HeLa IC50
    1.2 nM
    Compound: efavirenz, EFV
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase Y188C mutant in HeLa cells by MAGI assay
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase Y188C mutant in HeLa cells by MAGI assay
    [PMID: 18665583]
    HeLa IC50
    1.3 nM
    Compound: efavirenz, EFV
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase P225H mutant in HeLa cells by MAGI assay
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase P225H mutant in HeLa cells by MAGI assay
    [PMID: 18665583]
    HeLa IC50
    1.8 nM
    Compound: efavirenz, EFV
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V108I mutant in HeLa cells by MAGI assay
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V108I mutant in HeLa cells by MAGI assay
    [PMID: 18665583]
    HeLa IC50
    1198 nM
    Compound: efavirenz, EFV
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K103N/L100I mutant in HeLa cells by MAGI assay
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K103N/L100I mutant in HeLa cells by MAGI assay
    [PMID: 18665583]
    HeLa IC50
    140 nM
    Compound: efavirenz, EFV
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K103N/P225H mutant in HeLa cells by MAGI assay
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K103N/P225H mutant in HeLa cells by MAGI assay
    [PMID: 18665583]
    HeLa IC50
    154 nM
    Compound: efavirenz, EFV
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase Y188L mutant in HeLa cells by MAGI assay
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase Y188L mutant in HeLa cells by MAGI assay
    [PMID: 18665583]
    HeLa IC50
    17 nM
    Compound: efavirenz, EFV
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K103N mutant in HeLa cells by MAGI assay
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K103N mutant in HeLa cells by MAGI assay
    [PMID: 18665583]
    HeLa IC50
    2 nM
    Compound: efavirenz, EFV
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V106A/Y181C mutant in HeLa cells by MAGI assay
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V106A/Y181C mutant in HeLa cells by MAGI assay
    [PMID: 18665583]
    HeLa IC50
    2.3 nM
    Compound: efavirenz, EFV
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K101E mutant in HeLa cells by MAGI assay
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K101E mutant in HeLa cells by MAGI assay
    [PMID: 18665583]
    HeLa IC50
    2.7 nM
    Compound: efavirenz, EFV
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V108I/Y181C mutant in HeLa cells by MAGI assay
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V108I/Y181C mutant in HeLa cells by MAGI assay
    [PMID: 18665583]
    HeLa IC50
    21 nM
    Compound: efavirenz, EFV
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase L100I mutant in HeLa cells by MAGI assay
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase L100I mutant in HeLa cells by MAGI assay
    [PMID: 18665583]
    HeLa IC50
    3 nM
    Compound: efavirenz, EFV
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V106I/Y181C mutant in HeLa cells by MAGI assay
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V106I/Y181C mutant in HeLa cells by MAGI assay
    [PMID: 18665583]
    HeLa IC50
    44 nM
    Compound: efavirenz, EFV
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K103N/Y181C mutant in HeLa cells by MAGI assay
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K103N/Y181C mutant in HeLa cells by MAGI assay
    [PMID: 18665583]
    HeLa IC50
    485 nM
    Compound: efavirenz, EFV
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K103N/G190A mutant in HeLa cells by MAGI assay
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K103N/G190A mutant in HeLa cells by MAGI assay
    [PMID: 18665583]
    HeLa IC50
    5.9 nM
    Compound: efavirenz, EFV
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase G190A mutant in HeLa cells by MAGI assay
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase G190A mutant in HeLa cells by MAGI assay
    [PMID: 18665583]
    HeLa IC50
    7.2 nM
    Compound: efavirenz, EFV
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V106M mutant in HeLa cells by MAGI assay
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V106M mutant in HeLa cells by MAGI assay
    [PMID: 18665583]
    HeLa IC50
    89 nM
    Compound: efavirenz, EFV
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase G190S mutant in HeLa cells by MAGI assay
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase G190S mutant in HeLa cells by MAGI assay
    [PMID: 18665583]
    HeLa IC50
    94 nM
    Compound: efavirenz, EFV
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K103N/V108I mutant in HeLa cells by MAGI assay
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K103N/V108I mutant in HeLa cells by MAGI assay
    [PMID: 18665583]
    MRC5 IC50
    25.84 μM
    Compound: Efavirenz
    Cytotoxicity against human MRC5 SV2 cells assessed as reduction in cell growth after 72 hrs
    Cytotoxicity against human MRC5 SV2 cells assessed as reduction in cell growth after 72 hrs
    [PMID: 25199582]
    MRC5 IC50
    8.56 μM
    Compound: Efavirenz
    Trypanocidal activity against nifurtimox-sensitive Trypanosoma cruzi Tulahuen CL2 infected in human MRC5 SV2 cells assessed as parasite growth inhibition after 168 hrs by beta-galactosidase assay
    Trypanocidal activity against nifurtimox-sensitive Trypanosoma cruzi Tulahuen CL2 infected in human MRC5 SV2 cells assessed as parasite growth inhibition after 168 hrs by beta-galactosidase assay
    [PMID: 25199582]
    MT2 CC50
    > 0.1 μM
    Compound: Evafirenz
    Cytotoxicity against human MT2 cells by MTT assay
    Cytotoxicity against human MT2 cells by MTT assay
    [PMID: 20304641]
    MT2 CC50
    > 0.1 μM
    Compound: Evafirenz
    Cytotoxicity against human MT2 cells infected with HIV1 harboring reverse transcriptase Y181C mutation by MTT assay
    Cytotoxicity against human MT2 cells infected with HIV1 harboring reverse transcriptase Y181C mutation by MTT assay
    [PMID: 20304641]
    MT2 CC50
    > 0.1 μM
    Compound: Evafirenz
    Cytotoxicity against human MT2 cells infected with HIV1 harboring reverse transcriptase K103N/Y181C mutation by MTT assay
    Cytotoxicity against human MT2 cells infected with HIV1 harboring reverse transcriptase K103N/Y181C mutation by MTT assay
    [PMID: 20304641]
    MT2 EC50
    0.0001 μM
    Compound: EFV
    Antiviral activity against HIV1 subtype B-3B infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
    Antiviral activity against HIV1 subtype B-3B infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
    [PMID: 18316521]
    MT2 EC50
    0.0002 μM
    Compound: EFV
    Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA
    Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA
    [PMID: 18316521]
    MT2 EC50
    0.0002 μM
    Compound: EFV
    Antiviral activity against HIV1 subtype B-LAI infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
    Antiviral activity against HIV1 subtype B-LAI infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
    [PMID: 18316521]
    MT2 EC50
    0.0003 μM
    Compound: EFV
    Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA
    Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA
    [PMID: 18316521]
    MT2 EC50
    0.0003 μM
    Compound: EFV
    Antiviral activity against HIV1 subtype B-HXB2 infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
    Antiviral activity against HIV1 subtype B-HXB2 infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
    [PMID: 18316521]
    MT2 EC50
    0.0003 μM
    Compound: EFV
    Antiviral activity against HIV1 subtype B-RF infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
    Antiviral activity against HIV1 subtype B-RF infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
    [PMID: 18316521]
    MT2 EC50
    0.0003 μM
    Compound: EFV
    Antiviral activity against HIV1 subtype B-NL4-3 infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
    Antiviral activity against HIV1 subtype B-NL4-3 infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
    [PMID: 18316521]
    MT2 EC50
    0.00034 μM
    Compound: EFV
    Antiviral activity against pseudotype HIV1 NL-RLuc infected in human MT2 cells measured on day 5 postinfection by luciferase reporter gene assay
    Antiviral activity against pseudotype HIV1 NL-RLuc infected in human MT2 cells measured on day 5 postinfection by luciferase reporter gene assay
    [PMID: 18316521]
    MT2 EC50
    0.0004 μM
    Compound: EFV
    Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay
    Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay
    [PMID: 18316521]
    MT2 EC50
    0.0004 μM
    Compound: EFV
    Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA
    Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA
    [PMID: 18316521]
    MT2 EC50
    0.0004 μM
    Compound: EFV
    Antiviral activity against HIV1 subtype B-SF-2 infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
    Antiviral activity against HIV1 subtype B-SF-2 infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
    [PMID: 18316521]
    MT2 EC50
    0.0007 μM
    Compound: EFV
    Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay
    Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay
    [PMID: 18316521]
    MT2 EC50
    0.0007 μM
    Compound: EFV
    Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA
    Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA
    [PMID: 18316521]
    MT2 EC50
    0.0008 μM
    Compound: EFV
    Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay
    Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay
    [PMID: 18316521]
    MT2 EC50
    0.0009 μM
    Compound: EFV
    Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA
    Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA
    [PMID: 18316521]
    MT2 EC50
    0.0009 μM
    Compound: EFV
    Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA
    Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA
    [PMID: 18316521]
    MT2 EC50
    0.001 μM
    Compound: EFV
    Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay
    Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay
    [PMID: 18316521]
    MT2 EC50
    0.0011 μM
    Compound: EFV
    Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay
    Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay
    [PMID: 18316521]
    MT2 EC50
    0.0012 μM
    Compound: EFV
    Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay
    Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay
    [PMID: 18316521]
    MT2 EC50
    0.0012 μM
    Compound: EFV
    Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA
    Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA
    [PMID: 18316521]
    MT2 EC50
    0.0013 μM
    Compound: EFV
    Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay
    Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay
    [PMID: 18316521]
    MT2 EC50
    0.0017 μM
    Compound: EFV
    Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay
    Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay
    [PMID: 18316521]
    MT2 EC50
    0.002 μM
    Compound: efv
    Antiviral activity against wild type HIV1 3B infected in human MT2 cells assessed as protection from virus-induced cytopathicity by MTT assay
    Antiviral activity against wild type HIV1 3B infected in human MT2 cells assessed as protection from virus-induced cytopathicity by MTT assay
    [PMID: 25408842]
    MT2 EC50
    0.002 μM
    Compound: Efavirenz
    Antiviral activity against wild type HIV1 3B infected in human MT2 cells assessed as protection against virus-induced effect by MTT assay
    Antiviral activity against wild type HIV1 3B infected in human MT2 cells assessed as protection against virus-induced effect by MTT assay
    [PMID: 23937980]
    MT2 EC50
    0.002 μM
    Compound: Efavirenz
    Antiviral activity against HIV1 3B infected in human MT2 cells assessed as protection against virus-induced cytopathogenicity by MTT assay
    Antiviral activity against HIV1 3B infected in human MT2 cells assessed as protection against virus-induced cytopathogenicity by MTT assay
    [PMID: 23899617]
    MT2 EC50
    0.002 μM
    Compound: Evafirenz
    Antiviral activity against HIV1 3B infected in human MT2 cells assessed as inhibition of virus replication by MTT assay
    Antiviral activity against HIV1 3B infected in human MT2 cells assessed as inhibition of virus replication by MTT assay
    [PMID: 20304641]
    MT2 EC50
    0.002 μM
    Compound: Efavirenz
    Antiviral activity against multidrug resistant HIV1 IIIB containing reverse transcriptase infected in human MT2 cells assessed as cytoprotection from infection by MTT colorimetric method
    Antiviral activity against multidrug resistant HIV1 IIIB containing reverse transcriptase infected in human MT2 cells assessed as cytoprotection from infection by MTT colorimetric method
    [PMID: 23298809]
    MT2 EC50
    0.003 μM
    Compound: EFV
    Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA
    Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA
    [PMID: 18316521]
    MT2 EC50
    0.005 nM
    Compound: EFV, DMP-266, L-743, L-726
    Antiviral activity against HIV1 NL4-3 infected in human MT2 cells assessed as inhibition of virus-induced cell death at 0.005 multiplicities of infection after 6 days
    Antiviral activity against HIV1 NL4-3 infected in human MT2 cells assessed as inhibition of virus-induced cell death at 0.005 multiplicities of infection after 6 days
    [PMID: 20660667]
    MT2 EC50
    0.01 μM
    Compound: efv
    Antiviral activity against wild type HIV1 harboring reverse transcriptase Y181C mutant infected in human MT2 cells assessed as protection from virus-induced cytopathicity by MTT assay
    Antiviral activity against wild type HIV1 harboring reverse transcriptase Y181C mutant infected in human MT2 cells assessed as protection from virus-induced cytopathicity by MTT assay
    [PMID: 25408842]
    MT2 EC50
    0.01 μM
    Compound: Efavirenz
    Antiviral activity against HIV1 3B harboring reverse transcriptase Y181C mutant infected in human MT2 cells assessed as protection against virus-induced effect by MTT assay
    Antiviral activity against HIV1 3B harboring reverse transcriptase Y181C mutant infected in human MT2 cells assessed as protection against virus-induced effect by MTT assay
    [PMID: 23937980]
    MT2 EC50
    0.01 μM
    Compound: Evafirenz
    Antiviral activity against HIV1 reverse transcriptase Y181C mutant infected in human MT2 cells assessed as inhibition of viral replication by MTT assay
    Antiviral activity against HIV1 reverse transcriptase Y181C mutant infected in human MT2 cells assessed as inhibition of viral replication by MTT assay
    [PMID: 20304641]
    MT2 EC50
    0.01 μM
    Compound: Efavirenz
    Antiviral activity against multidrug resistant HIV1 IIIB containing reverse transcriptase Y181C mutation infected in human MT2 cells assessed as cytoprotection from infection by MTT colorimetric method
    Antiviral activity against multidrug resistant HIV1 IIIB containing reverse transcriptase Y181C mutation infected in human MT2 cells assessed as cytoprotection from infection by MTT colorimetric method
    [PMID: 23298809]
    MT2 EC50
    0.03 μM
    Compound: efv
    Antiviral activity against wild type HIV1 harboring reverse transcriptase K103N/Y181C mutant infected in human MT2 cells assessed as protection from virus-induced cytopathicity by MTT assay
    Antiviral activity against wild type HIV1 harboring reverse transcriptase K103N/Y181C mutant infected in human MT2 cells assessed as protection from virus-induced cytopathicity by MTT assay
    [PMID: 25408842]
    MT2 EC50
    0.03 μM
    Compound: Efavirenz
    Antiviral activity against HIV1 3B harboring reverse transcriptase K103N/Y181C double mutant infected in human MT2 cells assessed as protection against virus-induced effect by MTT assay
    Antiviral activity against HIV1 3B harboring reverse transcriptase K103N/Y181C double mutant infected in human MT2 cells assessed as protection against virus-induced effect by MTT assay
    [PMID: 23937980]
    MT2 EC50
    0.03 μM
    Compound: Evafirenz
    Antiviral activity against HIV1 reverse transcriptase K103N/Y181C double mutant infected in human MT2 cells assessed as inhibition of viral replication by MTT assay
    Antiviral activity against HIV1 reverse transcriptase K103N/Y181C double mutant infected in human MT2 cells assessed as inhibition of viral replication by MTT assay
    [PMID: 20304641]
    MT2 EC50
    0.03 μM
    Compound: Efavirenz
    Antiviral activity against multidrug resistant HIV1 IIIB containing reverse transcriptase K103N and Y181C mutation infected in human MT2 cells assessed as cytoprotection from infection by MTT colorimetric method
    Antiviral activity against multidrug resistant HIV1 IIIB containing reverse transcriptase K103N and Y181C mutation infected in human MT2 cells assessed as cytoprotection from infection by MTT colorimetric method
    [PMID: 23298809]
    MT2 EC50
    0.05 nM
    Compound: EFV, DMP-266, L-743, L-726
    Antiviral activity against HIV1 NL4-3 infected in human MT2 cells assessed as inhibition of virus-induced cell death at 0.05 multiplicities of infection after 6 days
    Antiviral activity against HIV1 NL4-3 infected in human MT2 cells assessed as inhibition of virus-induced cell death at 0.05 multiplicities of infection after 6 days
    [PMID: 20660667]
    MT2 EC50
    0.5 nM
    Compound: EFV, DMP-266, L-743, L-726
    Antiviral activity against HIV1 NL4-3 infected in human MT2 cells assessed as inhibition of virus-induced cell death at 0.5 multiplicities of infection after 6 days
    Antiviral activity against HIV1 NL4-3 infected in human MT2 cells assessed as inhibition of virus-induced cell death at 0.5 multiplicities of infection after 6 days
    [PMID: 20660667]
    MT2 EC50
    1.2 nM
    Compound: EFV
    Antiviral activity against vesicular stomatitis virus G-pseudotyped Human immunodeficiency virus 1 NL4-3 infected in human MT2 cells assessed as inhibition of viral replication after 48 hrs by luciferase activity reporter gene assay
    Antiviral activity against vesicular stomatitis virus G-pseudotyped Human immunodeficiency virus 1 NL4-3 infected in human MT2 cells assessed as inhibition of viral replication after 48 hrs by luciferase activity reporter gene assay
    [PMID: 21745701]
    MT2 EC50
    15 μM
    Compound: Efavirenz
    Cytotoxicity against human MT2 cells assessed as cell viability by MTT assay
    Cytotoxicity against human MT2 cells assessed as cell viability by MTT assay
    [PMID: 35175760]
    MT2 CC50
    15 μM
    Compound: Efavirenz
    Cytotoxicity against human MT2 cells assessed as growth inhibition by MTT method
    Cytotoxicity against human MT2 cells assessed as growth inhibition by MTT method
    [PMID: 27485603]
    MT2 CC50
    15 μM
    Compound: efv
    Cytotoxicity against human MT2 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human MT2 cells assessed as reduction in cell viability by MTT assay
    [PMID: 25408842]
    MT2 CC50
    15 μM
    Compound: Efavirenz
    Cytotoxicity against human MT2 cells by MTT assay
    Cytotoxicity against human MT2 cells by MTT assay
    [PMID: 23899617]
    MT2 CC50
    15 μM
    Compound: Efavirenz
    Cytotoxicity against human MT2 cells infected with HIV1 NL4.3 by MTT assay
    Cytotoxicity against human MT2 cells infected with HIV1 NL4.3 by MTT assay
    [PMID: 22081993]
    MT2 CC50
    3 μM
    Compound: 5
    Cytotoxicity against human MT2 cells by MTT assay
    Cytotoxicity against human MT2 cells by MTT assay
    [PMID: 17918923]
    MT2 EC50
    6.8 nM
    Compound: EFV
    Antiviral activity against HIV1 3B infected in human MT-2 cells by two fold dilution method in presence of 10% FBS
    Antiviral activity against HIV1 3B infected in human MT-2 cells by two fold dilution method in presence of 10% FBS
    [PMID: 19104010]
    MT4 EC50
    < 1 nM
    Compound: EFV
    Antiviral activity against NNRTI-resistant HIV HXB2 with reverse transcriptase 236L mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay
    Antiviral activity against NNRTI-resistant HIV HXB2 with reverse transcriptase 236L mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay
    [PMID: 19007201]
    MT4 EC50
    > 0.003 μM
    Compound: EFV
    Antiviral activity against Human immunodeficiency virus 1 infected human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
    Antiviral activity against Human immunodeficiency virus 1 infected human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
    10.1007/s00044-008-9149-5
    MT4 CC50
    > 0.00633 μM
    Compound: EFV
    Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay
    [PMID: 28481112]
    MT4 CC50
    > 0.3 μM
    Compound: EFV, efavirenz
    Cytotoxicity against MT4 cells after 4 days by MTT method
    Cytotoxicity against MT4 cells after 4 days by MTT method
    [PMID: 17910429]
    MT4 CC50
    > 0.32 μM
    Compound: Efavirenz
    Cytotoxicity against human MT4 cells by MTT assay
    Cytotoxicity against human MT4 cells by MTT assay
    [PMID: 19140683]
    MT4 CC50
    > 0.32 μM
    Compound: Efavirenz
    Cytotoxicity against MT4 cells by MTT assay
    Cytotoxicity against MT4 cells by MTT assay
    [PMID: 16621553]
    MT4 CC50
    > 0.32 μM
    Compound: EVZ
    Cytotoxicity against MT4 cells by MTT method
    Cytotoxicity against MT4 cells by MTT method
    [PMID: 16335924]
    MT4 CC50
    > 1 μg/mL
    Compound: EFV
    Cytotoxicity against human MT4 cells after 5 days by MTT assay
    Cytotoxicity against human MT4 cells after 5 days by MTT assay
    [PMID: 22652226]
    MT4 IC50
    > 10 μM
    Compound: Efavirenz
    Anti-HIV-1 activity against K103N+K1001 strain was determined in MT-4 cells by the MTT method
    Anti-HIV-1 activity against K103N+K1001 strain was determined in MT-4 cells by the MTT method
    [PMID: 14643315]
    MT4 EC50
    > 10 μM
    Compound: EFV, efavirenz
    Antiviral activity against HIV1 with reverse transcriptase Y188L mutation in MT4 cells assessed as inhibition of viral induced cytopathic effect by MTT method
    Antiviral activity against HIV1 with reverse transcriptase Y188L mutation in MT4 cells assessed as inhibition of viral induced cytopathic effect by MTT method
    [PMID: 17910429]
    MT4 EC50
    > 10 μM
    Compound: efavirenz
    Antiviral activity against HIV1 NL4-3 with double K103N/L100I mutant in human MT4 cells assessed as inhibition of virus-induced cytopathicity after 5 days by multiple round replication assay
    Antiviral activity against HIV1 NL4-3 with double K103N/L100I mutant in human MT4 cells assessed as inhibition of virus-induced cytopathicity after 5 days by multiple round replication assay
    [PMID: 19469474]
    MT4 EC50
    > 100 nM
    Compound: EFV
    Antiviral activity against NNRTI-resistant HIV HXB2 with reverse transcriptase 190S mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay
    Antiviral activity against NNRTI-resistant HIV HXB2 with reverse transcriptase 190S mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay
    [PMID: 19007201]
    MT4 IC50
    > 100 nM
    Compound: Efavirenz
    Antiviral activity against HIV1 harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect by replication assay in presence of 10% FBS
    Antiviral activity against HIV1 harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect by replication assay in presence of 10% FBS
    [PMID: 20829038]
    MT4 IC50
    > 100 nM
    Compound: Efavirenz
    Antiviral activity against HIV1 harboring reverse transcriptase K103N/L100I double mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect by replication assay in presence of 10% FBS
    Antiviral activity against HIV1 harboring reverse transcriptase K103N/L100I double mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect by replication assay in presence of 10% FBS
    [PMID: 20829038]
    MT4 CC50
    > 15839 nM
    Compound: EFV
    Cytotoxicity against mock-infected human MT4 cells measured after 5 days by MTT assay
    Cytotoxicity against mock-infected human MT4 cells measured after 5 days by MTT assay
    [PMID: 22712652]
    MT4 CC50
    > 15839 nM
    Compound: EFV
    Cytotoxicity against human MT-4 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human MT-4 cells assessed as reduction in cell viability by MTT assay
    [PMID: 32883642]
    MT4 CC50
    > 15839 nM
    Compound: EFV
    Cytotoxicity against human MT4 cells assessed as cell viability by MTT assay
    Cytotoxicity against human MT4 cells assessed as cell viability by MTT assay
    [PMID: 28628334]
    MT4 CC50
    > 15839 nM
    Compound: EFV, DMP-266
    Cytotoxic activity against human MT4 cells by MTT assay
    Cytotoxic activity against human MT4 cells by MTT assay
    [PMID: 25418038]
    MT4 CC50
    > 15839 nM
    Compound: EFV, DMP-266
    Cytotoxicity against human MT4 cells assessed as cell viability by MTT assay
    Cytotoxicity against human MT4 cells assessed as cell viability by MTT assay
    [PMID: 24769348]
    MT4 CC50
    > 2 μM
    Compound: 1; EFV
    Cytotoxicity against human MT4 cells measured after 5 days by MTT assay
    Cytotoxicity against human MT4 cells measured after 5 days by MTT assay
    [PMID: 31091477]
    MT4 CC50
    > 2 μM
    Compound: EFV
    Cytotoxicity against mock-infected human MT4 cells assessed as cell viability after 5 days by MTT assay
    Cytotoxicity against mock-infected human MT4 cells assessed as cell viability after 5 days by MTT assay
    [PMID: 23415090]
    MT4 CC50
    > 2000 nM
    Compound: EFV
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay
    [PMID: 29353724]
    MT4 CC50
    > 3 μM
    Compound: EFV
    Cytotoxicity against human MT4 cells assessed as induction of cell death by MTT method
    Cytotoxicity against human MT4 cells assessed as induction of cell death by MTT method
    [PMID: 24933420]
    MT4 CC50
    > 3 μM
    Compound: EFZ
    Cytotoxicity against human MT4 cells by MTT assay
    Cytotoxicity against human MT4 cells by MTT assay
    [PMID: 18630898]
    MT4 CC50
    > 3.16 μM
    Compound: 3; EFV
    Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
    Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
    [PMID: 30606670]
    MT4 CC50
    > 3000 nM
    Compound: EFV
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
    [PMID: 30525601]
    MT4 EC50
    > 31.68 μM
    Compound: Efavirenz
    Antiretroviral activity against Human immunodeficiency virus 2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    Antiretroviral activity against Human immunodeficiency virus 2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    [PMID: 18541726]
    MT4 EC50
    > 31.68 μM
    Compound: Efavirenz
    Antiretroviral activity against Human immunodeficiency virus 2 EHO infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    Antiretroviral activity against Human immunodeficiency virus 2 EHO infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    [PMID: 18541726]
    MT4 EC50
    > 31.68 μM
    Compound: Efavirenz
    Antiretroviral activity against Simian immunodeficiency virus MAC 251 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    Antiretroviral activity against Simian immunodeficiency virus MAC 251 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    [PMID: 18541726]
    MT4 EC50
    > 317 nM
    Compound: EFV, DMP-266
    Antiviral activity against HIV1 NL4-3 expressing reverse transcriptase K103N-Y181C mutant infected in human MT4 cells assessed as reduction in virus-induced cell death by MTT assay
    Antiviral activity against HIV1 NL4-3 expressing reverse transcriptase K103N-Y181C mutant infected in human MT4 cells assessed as reduction in virus-induced cell death by MTT assay
    [PMID: 25418038]
    MT4 EC50
    > 317 nM
    Compound: EFV, DMP-266
    Antiviral activity against HIV1 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method
    Antiviral activity against HIV1 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method
    [PMID: 24769348]
    MT4 CC50
    > 40196 nM
    Compound: Efavirenz
    Cytotoxicity against human MT4 cells assessed as cell viability by MTT assay
    Cytotoxicity against human MT4 cells assessed as cell viability by MTT assay
    [PMID: 35175760]
    MT4 CC50
    > 6 μM
    Compound: Efavirenz
    Cytotoxicity against human MT4 cells after 5 days
    Cytotoxicity against human MT4 cells after 5 days
    [PMID: 19616956]
    MT4 CC50
    > 6.3 μM
    Compound: EFV
    Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay
    Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay
    [PMID: 25707013]
    MT4 CC50
    > 6.3 μM
    Compound: EFV
    Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay
    Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay
    [PMID: 25626145]
    MT4 CC50
    > 6.3 μM
    Compound: EFV
    Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay
    Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay
    [PMID: 34496571]
    MT4 CC50
    > 6.3 μM
    Compound: EFV
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
    [PMID: 33352387]
    MT4 CC50
    > 6.3 μM
    Compound: 3; EFV
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay
    [PMID: 33340914]
    MT4 CC50
    > 6.3 μM
    Compound: EFV
    Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay
    [PMID: 27750153]
    MT4 CC50
    > 6.3 μM
    Compound: EFV
    Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
    Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
    [PMID: 27267005]
    MT4 CC50
    > 6.3 μM
    Compound: EFV
    Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay
    Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay
    [PMID: 24680058]
    MT4 CC50
    > 6.3 μM
    Compound: EFV, DMP266
    Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay
    [PMID: 24275349]
    MT4 CC50
    > 6.3 μM
    Compound: EFV
    Cytotoxicity against human MT4 cells after 5 days by MTT assay
    Cytotoxicity against human MT4 cells after 5 days by MTT assay
    [PMID: 24239481]
    MT4 CC50
    > 6.3 μM
    Compound: EFV
    Cytotoxicity against human MT4 cells after 5 days by MTT assay
    Cytotoxicity against human MT4 cells after 5 days by MTT assay
    [PMID: 22575532]
    MT4 CC50
    > 6.3 μM
    Compound: EFV
    Cytotoxicity against human MT4 cells after 5 days by MTT assay
    Cytotoxicity against human MT4 cells after 5 days by MTT assay
    [PMID: 22405288]
    MT4 CC50
    > 6.3 μM
    Compound: Efavirenz
    Cytotoxicity against human MT4 cells assessed as inhibition of cell viability by measuring reduction in absorbance at OD540 by MTT assay
    Cytotoxicity against human MT4 cells assessed as inhibition of cell viability by measuring reduction in absorbance at OD540 by MTT assay
    [PMID: 31767136]
    MT4 CC50
    > 6.3 μM
    Compound: EFV
    Cytotoxicity against human MT4 cells by MTT assay
    Cytotoxicity against human MT4 cells by MTT assay
    [PMID: 25150090]
    MT4 CC50
    > 6.3 μM
    Compound: 3, EFV
    Cytotoxicity against human MT4 cells by MTT assay
    Cytotoxicity against human MT4 cells by MTT assay
    [PMID: 24794751]
    MT4 CC50
    > 6.3 μM
    Compound: EFV
    Cytotoxicity against HIV2 ROD infected in human MT4 cells by MTT assay
    Cytotoxicity against HIV2 ROD infected in human MT4 cells by MTT assay
    [PMID: 23098609]
    MT4 CC50
    > 6.3 μM
    Compound: EFV
    Cytotoxicity against HIV1 3B infected in human MT4 cells by MTT assay
    Cytotoxicity against HIV1 3B infected in human MT4 cells by MTT assay
    [PMID: 23098609]
    MT4 CC50
    > 6.3 μM
    Compound: EFV
    Cytotoxicity against human MT4 cells by MTT assay
    Cytotoxicity against human MT4 cells by MTT assay
    [PMID: 23084898]
    MT4 CC50
    > 6.3 μM
    Compound: EFV
    Cytotoxicity against mock-infected human MT4 cells by MTT assay
    Cytotoxicity against mock-infected human MT4 cells by MTT assay
    [PMID: 22883027]
    MT4 CC50
    > 6.3 μM
    Compound: Efavirenz
    Cytotoxicity against human MT4 cells after 5 days MTT assay
    Cytotoxicity against human MT4 cells after 5 days MTT assay
    [PMID: 27112451]
    MT4 CC50
    > 6.33 μM
    Compound: Efavirenz
    Cytotoxicity against human MT4 cells after 4 days by MTT assay
    Cytotoxicity against human MT4 cells after 4 days by MTT assay
    [PMID: 21824782]
    MT4 CC50
    > 6.33 μM
    Compound: EFV
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay
    [PMID: 35073089]
    MT4 CC50
    > 6.33 μM
    Compound: EFV
    Cytotoxicity against in human MT-4 cells after 5 days by MTT assay
    Cytotoxicity against in human MT-4 cells after 5 days by MTT assay
    [PMID: 33851529]
    MT4 CC50
    > 6.33 μM
    Compound: Efavirenz
    Cytotoxicity against human MT4 cells after 5 days by MTT assay
    Cytotoxicity against human MT4 cells after 5 days by MTT assay
    [PMID: 29291935]
    MT4 CC50
    > 6.33 μM
    Compound: Efavirenz
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
    [PMID: 28559060]
    MT4 CC50
    > 6.33 μM
    Compound: 3; EFV
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 to 7 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 to 7 days by MTT assay
    [PMID: 35640327]
    MT4 CC50
    > 6.33 μM
    Compound: EFV
    Cytotoxicity against mock infected human MT4 cells by MTT assay
    Cytotoxicity against mock infected human MT4 cells by MTT assay
    [PMID: 34197708]
    MT4 CC50
    > 6.335 μM
    Compound: EFV
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
    [PMID: 33567378]
    MT4 CC50
    > 6.336 μM
    Compound: EFV
    Cytotoxicity against human MT4 cells as reduction in cell viability after 5 days by MTT assay
    Cytotoxicity against human MT4 cells as reduction in cell viability after 5 days by MTT assay
    [PMID: 19628308]
    MT4 CC50
    > 6.336 μM
    Compound: EFV
    Cytotoxicity against Homo sapiens (human) MT4 cells by MTT assay
    Cytotoxicity against Homo sapiens (human) MT4 cells by MTT assay
    10.1007/s00044-009-9220-x
    MT4 CC50
    > 6.336 μM
    Compound: EFV
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay
    [PMID: 29670703]
    MT4 CC50
    > 6.336 μM
    Compound: EFV
    Cytotoxicity against human MT4 cells by MTT assay
    Cytotoxicity against human MT4 cells by MTT assay
    [PMID: 19643613]
    MT4 CC50
    > 6.34 μM
    Compound: EFV
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 4 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 4 days by MTT assay
    [PMID: 31421633]
    MT4 CC50
    > 6.34 μM
    Compound: EFV
    Cytotoxicity against mock infected human MT4 cells after 4 days by MTT assay
    Cytotoxicity against mock infected human MT4 cells after 4 days by MTT assay
    [PMID: 26994843]
    MT4 CC50
    > 6.34 μM
    Compound: EFV
    Cytotoxicity against human MT4 cells after 4 days by MTT assay
    Cytotoxicity against human MT4 cells after 4 days by MTT assay
    [PMID: 20307984]
    MT4 CC50
    > 6.34 μM
    Compound: Efavirenz
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
    [PMID: 33979774]
    MT4 CC50
    > 6.34 μM
    Compound: 3; EFV
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
    [PMID: 32977301]
    MT4 CC50
    > 6.34 μM
    Compound: EFV
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
    [PMID: 32712537]
    MT4 CC50
    > 6.34 μM
    Compound: EFV
    Cytotoxicity in mock-infected human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
    Cytotoxicity in mock-infected human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
    [PMID: 31935327]
    MT4 CC50
    > 6.34 μM
    Compound: EFV
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
    [PMID: 31735575]
    MT4 CC50
    > 6.34 μM
    Compound: EFV
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
    [PMID: 31714780]
    MT4 CC50
    > 6.34 μM
    Compound: EFV
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
    [PMID: 30721060]
    MT4 CC50
    > 6.34 μM
    Compound: EFV
    Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay
    [PMID: 29635166]
    MT4 CC50
    > 6.34 μM
    Compound: EFV
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
    [PMID: 29559197]
    MT4 CC50
    > 6.34 μM
    Compound: EFV
    Cytotoxicity against human MT4 cells after 5 days by MTT assay
    Cytotoxicity against human MT4 cells after 5 days by MTT assay
    [PMID: 29534929]
    MT4 CC50
    > 6.34 μM
    Compound: EFV
    Cytotoxicity against human MT4 cells after 5 days by MTT assay
    Cytotoxicity against human MT4 cells after 5 days by MTT assay
    [PMID: 28254696]
    MT4 CC50
    > 6.34 μM
    Compound: Efavirenz
    Cytotoxicity against uninfected human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay
    Cytotoxicity against uninfected human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay
    [PMID: 26385446]
    MT4 CC50
    > 6.34 μM
    Compound: EFV
    Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay
    Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay
    [PMID: 25240095]
    MT4 CC50
    > 6.34 μM
    Compound: EFV
    Cytotoxicity against human MT4 cells assessed as growth inhibition after 5 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as growth inhibition after 5 days by MTT assay
    [PMID: 24602795]
    MT4 CC50
    > 6.34 μM
    Compound: EFV
    Cytotoxicity against human MT4 cells after 5 days by MTT assay
    Cytotoxicity against human MT4 cells after 5 days by MTT assay
    [PMID: 23707918]
    MT4 EC50
    > 6.34 μM
    Compound: EFV
    Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
    [PMID: 23707918]
    MT4 CC50
    > 6.34 μM
    Compound: EFV
    Cytotoxicity against human MT4 cells after 5 days by MTT assay
    Cytotoxicity against human MT4 cells after 5 days by MTT assay
    [PMID: 22591854]
    MT4 CC50
    > 6.34 μM
    Compound: EFV
    Cytotoxic activity against human MT4 cells assessed as viability of mock-infected cells after 5 days by MTT assay
    Cytotoxic activity against human MT4 cells assessed as viability of mock-infected cells after 5 days by MTT assay
    [PMID: 21683601]
    MT4 CC50
    > 6.34 μM
    Compound: EFV
    Cytotoxicity against mock-infected human MT4 cells assessed as decrease in cell viability measured 5 days post-infection by MTT assay
    Cytotoxicity against mock-infected human MT4 cells assessed as decrease in cell viability measured 5 days post-infection by MTT assay
    10.1039/C3MD00247K
    MT4 CC50
    > 6.34 μM
    Compound: EFV
    Cytotoxicity against HIV-2 ROD mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against HIV-2 ROD mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay
    10.1039/C3MD00028A
    MT4 CC50
    > 6.34 μM
    Compound: EFV
    Cytotoxicity against HIV-1 3B mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against HIV-1 3B mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay
    10.1039/C3MD00028A
    MT4 CC50
    > 6.34 μM
    Compound: Efavirenz
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay
    [PMID: 35649164]
    MT4 CC50
    > 6.34 μM
    Compound: EFV
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay
    [PMID: 34432448]
    MT4 CC50
    > 6.34 μM
    Compound: EFV
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay
    [PMID: 33279288]
    MT4 CC50
    > 6.34 μM
    Compound: EFV
    Cytotoxicity in mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity in mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay
    [PMID: 28987601]
    MT4 CC50
    > 6.34 μM
    Compound: Efavirenz
    Cytotoxicity against human MT4 cells measured by MTT assay
    Cytotoxicity against human MT4 cells measured by MTT assay
    [PMID: 22037050]
    MT4 CC50
    > 6.34 μM
    Compound: EFV
    Cytotoxicity against human MT4 cells after 5 days MTT assay
    Cytotoxicity against human MT4 cells after 5 days MTT assay
    [PMID: 25537532]
    MT4 CC50
    > 6.35 μM
    Compound: EFV
    Cytotoxicity against mock-infected human MT4 cells incubated for 5 days by MTT assay
    Cytotoxicity against mock-infected human MT4 cells incubated for 5 days by MTT assay
    [PMID: 34090079]
    MT4 CC50
    > 6.35 μM
    Compound: 3; EFV
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
    [PMID: 31434039]
    MT4 CC50
    > 6.38 μM
    Compound: EFV
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
    [PMID: 32200201]
    MT4 CC50
    > 6.5 μM
    Compound: EFV
    Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay
    Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay
    [PMID: 25907370]
    MT4 CC50
    > 63 μM
    Compound: Efavirenz, Sustiva
    Cytotoxicity against human MT4 cells after 4 days by MTT assay
    Cytotoxicity against human MT4 cells after 4 days by MTT assay
    [PMID: 21903401]
    MT4 CC50
    > 63.36 μM
    Compound: EFV
    Cytotoxicity against human MT4 cells after 4 days by MTT assay
    Cytotoxicity against human MT4 cells after 4 days by MTT assay
    [PMID: 20570527]
    MT4 CC50
    > 6336 nM
    Compound: 3, EFV
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 4 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 4 days by MTT assay
    [PMID: 26276435]
    MT4 CC50
    > 6336 nM
    Compound: EFV
    Cytotoxicity against human MT4 cells assessed as reduction of cell viability after 4 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as reduction of cell viability after 4 days by MTT assay
    [PMID: 25935383]
    MT4 CC50
    > 6340 nM
    Compound: EFV
    Cytotoxicity against human mock-infected MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
    Cytotoxicity against human mock-infected MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
    [PMID: 27541578]
    MT4 CC50
    > 6340 nM
    Compound: EFV
    Toxicity in mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay
    Toxicity in mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay
    [PMID: 34890994]
    MT4 CC50
    > 9 μM
    Compound: Efavirenz
    Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay
    [PMID: 28314598]
    MT4 CC50
    ≥ 6.3 μM
    Compound: EFV
    Cytotoxicity against human MT4 cells after 4 days by MTT assay
    Cytotoxicity against human MT4 cells after 4 days by MTT assay
    [PMID: 20598556]
    MT4 CC50
    ≥ 6.34 μM
    Compound: EFV
    Cytotoxicity against mock-infected human MT4 cells assessed as reduction of cell viability after 5 days by MTT assay
    Cytotoxicity against mock-infected human MT4 cells assessed as reduction of cell viability after 5 days by MTT assay
    [PMID: 27501911]
    MT4 EC50
    0.0007 μM
    Compound: 2; EFV
    Antiviral activity against HIV1 BH10 harboring wild type reverse transcriptase infected in primary MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTS assay
    Antiviral activity against HIV1 BH10 harboring wild type reverse transcriptase infected in primary MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTS assay
    [PMID: 26804933]
    MT4 EC50
    0.0009 μM
    Compound: Efavirenz
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed inhibition of viral-induced cytopathic effect after 5 days
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed inhibition of viral-induced cytopathic effect after 5 days
    [PMID: 20097079]
    MT4 EC50
    0.0009 μM
    Compound: Efavirenz
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days
    [PMID: 19616956]
    MT4 EC50
    0.0009 μM
    Compound: Efavirenz
    Antiviral activity against HIV1 3B in human MT4 cells assessed as virus-induced cytopathogenicity after 5 days
    Antiviral activity against HIV1 3B in human MT4 cells assessed as virus-induced cytopathogenicity after 5 days
    [PMID: 18585918]
    MT4 EC50
    0.00095 μM
    Compound: Efavirenz
    Antiviral activity against Reverse transcriptase inhibitor-resistant Human immunodeficiency virus 1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    Antiviral activity against Reverse transcriptase inhibitor-resistant Human immunodeficiency virus 1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    [PMID: 18541726]
    MT4 IC50
    0.001 μM
    Compound: Efavirenz
    Anti-HIV-1 activity against LAI strain in MT-4 cells by the MTT method
    Anti-HIV-1 activity against LAI strain in MT-4 cells by the MTT method
    [PMID: 14643315]
    MT4 EC50
    0.001 μM
    Compound: Efavirenz
    Antiviral activity against wild type HIV1 NL4-3 infected in human MT4 cells after 5 days by MTT assay
    Antiviral activity against wild type HIV1 NL4-3 infected in human MT4 cells after 5 days by MTT assay
    [PMID: 19140683]
    MT4 ED50
    0.001 μM
    Compound: EFV
    Antiviral activity against wild type HIV1 NL4-3 infected in human MT4 cells assessed as virus-induced cell death by MTT method
    Antiviral activity against wild type HIV1 NL4-3 infected in human MT4 cells assessed as virus-induced cell death by MTT method
    [PMID: 18842407]
    MT4 EC50
    0.001 μM
    Compound: Efavirenz
    Antiviral activity against wild type HIV1 NL4-3 in MT4 cells by MTT assay
    Antiviral activity against wild type HIV1 NL4-3 in MT4 cells by MTT assay
    [PMID: 16621553]
    MT4 EC50
    0.001 μM
    Compound: EVZ
    Antiviral activity against wild type HIV1 NL4-3 infected MT4 cells by MTT method
    Antiviral activity against wild type HIV1 NL4-3 infected MT4 cells by MTT method
    [PMID: 16335924]
    MT4 EC50
    0.001 μM
    Compound: efavirenz
    Antiviral activity against HIV1 3B in human MT4 cells by XTT assay
    Antiviral activity against HIV1 3B in human MT4 cells by XTT assay
    [PMID: 17803290]
    MT4 EC50
    0.001 μM
    Compound: Efavirenz
    Inhibition of wild type HIV-1 3B reverse transcriptase infected in human MT4 cells assessed as inhibition of viral replication after 5 days by cell titer glo based luciferase reporter gene assay
    Inhibition of wild type HIV-1 3B reverse transcriptase infected in human MT4 cells assessed as inhibition of viral replication after 5 days by cell titer glo based luciferase reporter gene assay
    [PMID: 27371922]
    MT4 EC50
    0.0016 μM
    Compound: Efavirenz
    Antiviral activity against Protease inhibitor-resistant Human immunodeficiency virus 1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    Antiviral activity against Protease inhibitor-resistant Human immunodeficiency virus 1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    [PMID: 18541726]
    MT4 EC50
    0.0018 μM
    Compound: 2; EFV
    Antiviral activity against HIV1 harboring reverse transcriptase K103N mutant infected in primary MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTS assay
    Antiviral activity against HIV1 harboring reverse transcriptase K103N mutant infected in primary MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTS assay
    [PMID: 26804933]
    MT4 EC50
    0.0019 μM
    Compound: Efavirenz
    Antiretroviral activity against Human immunodeficiency virus 1 NL4.3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    Antiretroviral activity against Human immunodeficiency virus 1 NL4.3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    [PMID: 18541726]
    MT4 IC50
    0.002 μM
    Compound: Efavirenz
    Anti-HIV-1 activity against K1001 strain was determined in MT-4 cells by the MTT method
    Anti-HIV-1 activity against K1001 strain was determined in MT-4 cells by the MTT method
    [PMID: 14643315]
    MT4 EC50
    0.002 μM
    Compound: EFV
    Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 4 days by MTT assay
    Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 4 days by MTT assay
    [PMID: 26479028]
    MT4 EC50
    0.002 μM
    Compound: efavirenz
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay
    [PMID: 26358281]
    MT4 EC50
    0.002 μM
    Compound: EFV
    Antiviral activity against HIV1 infected in human MT4 cells assessed as protection against viral-induced cytopathogenecity after 4 days by MTT method
    Antiviral activity against HIV1 infected in human MT4 cells assessed as protection against viral-induced cytopathogenecity after 4 days by MTT method
    [PMID: 25913116]
    MT4 EC50
    0.002 μM
    Compound: EFV
    Antiviral activity against HIV-13B infected in MT4 cells assessed as protection from virus-induced cytopathogenicity after 4 days by MTT method
    Antiviral activity against HIV-13B infected in MT4 cells assessed as protection from virus-induced cytopathogenicity after 4 days by MTT method
    [PMID: 25014745]
    MT4 EC50
    0.002 μM
    Compound: EFV, DMP266, L-743,726
    Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
    Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
    [PMID: 24805780]
    MT4 EC50
    0.002 μM
    Compound: EFV, DMP266, L-743,726
    Antiviral activity against zidovudine-resistant HIV1 harboring RT 67N, 70R, 215F, 219Q mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
    Antiviral activity against zidovudine-resistant HIV1 harboring RT 67N, 70R, 215F, 219Q mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
    [PMID: 24805780]
    MT4 EC50
    0.002 μM
    Compound: Efavirenz
    Antiviral activity against Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
    Antiviral activity against Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
    [PMID: 24489455]
    MT4 EC50
    0.002 μM
    Compound: EFV
    Antiviral activity against HIV1 infected in human MT4 cells assessed as virus-induced cytopathogenicity after 4 days by MTT assay
    Antiviral activity against HIV1 infected in human MT4 cells assessed as virus-induced cytopathogenicity after 4 days by MTT assay
    [PMID: 22884523]
    MT4 EC50
    0.002 μM
    Compound: Efavirenz
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
    [PMID: 22513121]
    MT4 EC50
    0.002 μM
    Compound: EFV
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
    [PMID: 22047799]
    MT4 EC50
    0.002 μM
    Compound: EFV
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay
    [PMID: 19775780]
    MT4 EC50
    0.002 μM
    Compound: Efavirenz
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity by MTT assay
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity by MTT assay
    [PMID: 26119992]
    MT4 EC50
    0.0027 μM
    Compound: EFV
    Antiviral activity against HIV-1 3B expressing wild type reverse transcriptase infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    Antiviral activity against HIV-1 3B expressing wild type reverse transcriptase infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    [PMID: 27234889]
    MT4 EC50
    0.003 μM
    Compound: Efavirenz, Sustiva
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay
    [PMID: 21903401]
    MT4 EC50
    0.003 μM
    Compound: EFV
    Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay
    Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay
    [PMID: 20570527]
    MT4 EC50
    0.003 μM
    Compound: EFV
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection from virus-induced cytopathogenicity after 4 days by MTT assay
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection from virus-induced cytopathogenicity after 4 days by MTT assay
    [PMID: 20307984]
    MT4 EC50
    0.003 μM
    Compound: EFV
    Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as protection against virus induced cytopathogenicity after 4 days by MTT assay
    Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as protection against virus induced cytopathogenicity after 4 days by MTT assay
    [PMID: 19781821]
    MT4 EC50
    0.003 μM
    Compound: Efavirenz
    Antiviral activity against HIV1 reverse transcriptase Y188L mutant infected in human MT4 cells after 5 days by MTT assay
    Antiviral activity against HIV1 reverse transcriptase Y188L mutant infected in human MT4 cells after 5 days by MTT assay
    [PMID: 19140683]
    MT4 EC50
    0.003 μM
    Compound: efavirenz
    Antiviral activity against HIV1 3B infected in MT4 cells by MTT
    Antiviral activity against HIV1 3B infected in MT4 cells by MTT
    [PMID: 18267363]
    MT4 EC50
    0.003 μM
    Compound: EFV
    Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days
    Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days
    [PMID: 22652226]
    MT4 EC50
    0.003 μM
    Compound: efavirenz
    Antiviral activity against wild type HIV1 NL4-3 in human MT4 cells assessed as inhibition of virus-induced cytopathicity after 5 days by multiple round replication assay
    Antiviral activity against wild type HIV1 NL4-3 in human MT4 cells assessed as inhibition of virus-induced cytopathicity after 5 days by multiple round replication assay
    [PMID: 19469474]
    MT4 EC50
    0.004 μM
    Compound: Efavirenz
    Concentration required for 50% protection of infected MT-4 cells from wtIIIB-HIV-1-induced cytopathogenicity was determined by the MTT method
    Concentration required for 50% protection of infected MT-4 cells from wtIIIB-HIV-1-induced cytopathogenicity was determined by the MTT method
    [PMID: 15634015]
    MT4 EC50
    0.004 μM
    Compound: EFV, DMP266, L-743,726
    Antiviral activity against MDR-resistant HIV1 harboring 41L, 74V, 106A, 215Y mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
    Antiviral activity against MDR-resistant HIV1 harboring 41L, 74V, 106A, 215Y mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
    [PMID: 24805780]
    MT4 EC50
    0.004 μM
    Compound: EFV, DMP266, L-743,726
    Antiviral activity against saquinavir-resistant HIV1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
    Antiviral activity against saquinavir-resistant HIV1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
    [PMID: 24805780]
    MT4 EC50
    0.004 μM
    Compound: EFV, efavirenz
    Antiviral activity against HIV1 NL43 in MT4 cells assessed as inhibition of viral induced cytopathic effect after 4 days by MTT method
    Antiviral activity against HIV1 NL43 in MT4 cells assessed as inhibition of viral induced cytopathic effect after 4 days by MTT method
    [PMID: 17910429]
    MT4 EC50
    0.004 μM
    Compound: EFV
    Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    [PMID: 27234889]
    MT4 EC50
    0.004 μM
    Compound: efavirenz
    Antiviral activity against HIV1 NL4-3 with Y181C mutant in human MT4 cells assessed as inhibition of virus-induced cytopathicity after 5 days by multiple round replication assay
    Antiviral activity against HIV1 NL4-3 with Y181C mutant in human MT4 cells assessed as inhibition of virus-induced cytopathicity after 5 days by multiple round replication assay
    [PMID: 19469474]
    MT4 IC50
    0.004 μM
    Compound: Efavirenz
    Concentration required to protect the cell against HIV-1 strain IIIB viral cytopathogenicity by 50% in MT-4 cells
    Concentration required to protect the cell against HIV-1 strain IIIB viral cytopathogenicity by 50% in MT-4 cells
    [PMID: 15149669]
    MT4 EC50
    0.0044 μM
    Compound: EFV
    Antiviral activity against Human immunodeficiency virus 1 IIIB infected human MT4 cells assessed as inhibition of virus-induced cytopathicity after 4 days by MTT assay
    Antiviral activity against Human immunodeficiency virus 1 IIIB infected human MT4 cells assessed as inhibition of virus-induced cytopathicity after 4 days by MTT assay
    10.1007/s00044-009-9220-x
    MT4 EC50
    0.0044 μM
    Compound: EFV
    Antiviral activity against wild type Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay
    Antiviral activity against wild type Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay
    [PMID: 21683601]
    MT4 EC50
    0.0044 μM
    Compound: EFV
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus induced cytotoxicity after 5 days by MTT assay
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus induced cytotoxicity after 5 days by MTT assay
    [PMID: 19628308]
    MT4 EC50
    0.0044 μM
    Compound: EFV
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as virus-induced cytopathic effect by MTT assay
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as virus-induced cytopathic effect by MTT assay
    [PMID: 19643613]
    MT4 EC50
    0.005 μM
    Compound: EFV
    Antiviral activity against HIV-1 infected in MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
    Antiviral activity against HIV-1 infected in MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
    [PMID: 26443549]
    MT4 EC50
    0.005 μM
    Compound: EFV
    Antiviral activity against HIV1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
    Antiviral activity against HIV1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
    [PMID: 25082514]
    MT4 EC50
    0.005 μM
    Compound: Efavirenz
    Antiviral activity against wild type Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay
    Antiviral activity against wild type Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay
    [PMID: 21824782]
    MT4 EC50
    0.005 μM
    Compound: EFV
    Antiviral activity against HIV1 3B expressing reverse transcriptase E138K mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against HIV1 3B expressing reverse transcriptase E138K mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay
    [PMID: 26802545]
    MT4 EC50
    0.005 μM
    Compound: EFV
    Antiviral activity against HIV1 3B harboring wild type RT infected in MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against HIV1 3B harboring wild type RT infected in MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
    [PMID: 22575532]
    MT4 EC50
    0.005 μM
    Compound: EFV
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    [PMID: 23098609]
    MT4 EC50
    0.005 μM
    Compound: EFV
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay
    [PMID: 23084898]
    MT4 EC50
    0.005 μM
    Compound: Efavirenz
    Inhibition of reverse transcriptase Y181C mutant in HIV-1 3B infected in human MT4 cells assessed as inhibition of viral replication after 5 days by cell titer glo based luciferase reporter gene assay
    Inhibition of reverse transcriptase Y181C mutant in HIV-1 3B infected in human MT4 cells assessed as inhibition of viral replication after 5 days by cell titer glo based luciferase reporter gene assay
    [PMID: 27371922]
    MT4 EC50
    0.0053 μM
    Compound: EFV
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity by MTT assay
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity by MTT assay
    [PMID: 25150090]
    MT4 EC50
    0.0054 μM
    Compound: EFV
    Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as cell viability after 4 days by MTT assay
    Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as cell viability after 4 days by MTT assay
    [PMID: 26994843]
    MT4 EC50
    0.0054 μM
    Compound: EFV
    Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay
    [PMID: 26802545]
    MT4 EC50
    0.0054 μM
    Compound: EFV
    Antiviral activity against wild-type HIV1 3B infected in human MT4 cells assessed as protection of cells from virus-induced cytopathic after 5 days by MTT assay
    Antiviral activity against wild-type HIV1 3B infected in human MT4 cells assessed as protection of cells from virus-induced cytopathic after 5 days by MTT assay
    [PMID: 25907370]
    MT4 EC50
    0.0054 μM
    Compound: Efavirenz
    Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity after 5 days by MTT assay
    Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity after 5 days by MTT assay
    [PMID: 22037050]
    MT4 EC50
    0.0054 μM
    Compound: EFV
    Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay
    Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay
    10.1039/C3MD00028A
    MT4 EC50
    0.0055 μM
    Compound: EFV
    Antiviral activity against HIV-1 3B harboring RT E138K mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay
    Antiviral activity against HIV-1 3B harboring RT E138K mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay
    [PMID: 21872971]
    MT4 EC50
    0.0057 μM
    Compound: EFV
    Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay
    Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay
    [PMID: 24602795]
    MT4 EC50
    0.006 μM
    Compound: Efavirenz
    Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay
    [PMID: 27112451]
    MT4 EC50
    0.006 μM
    Compound: EFV
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay
    [PMID: 25707013]
    MT4 EC50
    0.006 μM
    Compound: 3, EFV
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post viral infection by MTT assay
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post viral infection by MTT assay
    [PMID: 24794751]
    MT4 EC50
    0.006 μM
    Compound: EFV, efavirenz
    Antiviral activity against HIV1 with reverse transcriptase Y181C mutation in MT4 cells assessed as inhibition of viral induced cytopathic effect by MTT method
    Antiviral activity against HIV1 with reverse transcriptase Y181C mutation in MT4 cells assessed as inhibition of viral induced cytopathic effect by MTT method
    [PMID: 17910429]
    MT4 EC50
    0.006 μM
    Compound: Efavirenz
    Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days
    Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days
    [PMID: 24457088]
    MT4 EC50
    0.0062 μM
    Compound: EFV
    Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay
    [PMID: 25537532]
    MT4 EC50
    0.0063 μM
    Compound: Efavirenz
    Antiviral activity against wild type HIV 1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay
    Antiviral activity against wild type HIV 1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay
    [PMID: 26385446]
    MT4 EC50
    0.0063 μM
    Compound: EFV
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay
    [PMID: 25240095]
    MT4 EC50
    0.0067 μM
    Compound: EFV
    Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay
    Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay
    [PMID: 24055077]
    MT4 EC50
    0.0068 μM
    Compound: EFV
    Antiviral activity against HIV1 3B expressing wild type reverse transcriptase infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against HIV1 3B expressing wild type reverse transcriptase infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay
    [PMID: 27267005]
    MT4 EC50
    0.0068 μM
    Compound: EFV
    Antiviral activity against HIV1 3B expressing reverse transcriptase Y181C mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against HIV1 3B expressing reverse transcriptase Y181C mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay
    [PMID: 26802545]
    MT4 EC50
    0.007 μM
    Compound: EFV
    Antiviral activity against HIV1 3B infected in human MT-4 cells assessed as protection against virus-induced cytopathicity after 5 days by MTT assay
    Antiviral activity against HIV1 3B infected in human MT-4 cells assessed as protection against virus-induced cytopathicity after 5 days by MTT assay
    [PMID: 24239481]
    MT4 EC50
    0.007 μM
    Compound: EFV
    Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathicity after 5 days by MTT assay
    Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathicity after 5 days by MTT assay
    [PMID: 23415090]
    MT4 EC50
    0.007 μM
    Compound: EFV
    Antiviral activity against wild type HIV-1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT method
    Antiviral activity against wild type HIV-1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT method
    [PMID: 24933420]
    MT4 EC50
    0.007 μM
    Compound: EFZ
    Antiviral activity against HIV1 NL4-3 in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay
    Antiviral activity against HIV1 NL4-3 in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay
    [PMID: 18630898]
    MT4 EC50
    0.0074 μM
    Compound: EFV, DMP266
    Antiviral activity against wild-type HIV1 3B infected in human MT4 cells assessed as inhibition of viral cytopathicity after 5 days by MTT assay
    Antiviral activity against wild-type HIV1 3B infected in human MT4 cells assessed as inhibition of viral cytopathicity after 5 days by MTT assay
    [PMID: 24275349]
    MT4 EC50
    0.008 μM
    Compound: Efavirenz
    Antiviral activity against HIV1 reverse transcriptase Y181C mutant infected in human MT4 cells after 5 days by MTT assay
    Antiviral activity against HIV1 reverse transcriptase Y181C mutant infected in human MT4 cells after 5 days by MTT assay
    [PMID: 19140683]
    MT4 ED50
    0.008 μM
    Compound: EFV
    Antiviral activity against drug-resistant HIV1 with reverse transcriptase Y181C mutant infected in human MT4 cells assessed as virus-induced cell death by MTT method
    Antiviral activity against drug-resistant HIV1 with reverse transcriptase Y181C mutant infected in human MT4 cells assessed as virus-induced cell death by MTT method
    [PMID: 18842407]
    MT4 EC50
    0.0089 μM
    Compound: EFV
    Antiviral activity against wild-type HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathic effect measured 5 days post-infection by MTT assay
    Antiviral activity against wild-type HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathic effect measured 5 days post-infection by MTT assay
    10.1039/C3MD00247K
    MT4 EC50
    0.009 μM
    Compound: EFV
    Antiviral activity against wild-type HIV1 3B infected in MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against wild-type HIV1 3B infected in MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay
    [PMID: 24134904]
    MT4 EC50
    0.01 μM
    Compound: EFV, DMP266, L-743,726
    Antiviral activity against N119-sensitive HIV1 harboring Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
    Antiviral activity against N119-sensitive HIV1 harboring Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
    [PMID: 24805780]
    MT4 EC50
    0.01 μM
    Compound: EFV
    Antiviral activity against NNRTI-resistant HIV1 N119 with reverse transcriptase Y181C mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay
    Antiviral activity against NNRTI-resistant HIV1 N119 with reverse transcriptase Y181C mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay
    [PMID: 19775780]
    MT4 EC50
    0.01 μM
    Compound: EFV
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
    [PMID: 23707918]
    MT4 EC50
    0.01 μM
    Compound: Efavirenz
    Antiviral activity against HIV1 3B expressing reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay
    Antiviral activity against HIV1 3B expressing reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay
    [PMID: 19058881]
    MT4 EC50
    0.01 μM
    Compound: table 6,efavirenz
    Antiviral activity against HIV1 with reverse transcriptase Y181C mutation in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay
    Antiviral activity against HIV1 with reverse transcriptase Y181C mutation in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay
    [PMID: 18226533]
    MT4 EC50
    0.01 μM
    Compound: efavirenz
    Antiviral activity against HIV1 with reverse transcriptase K103N/Y181C mutation in human MT4 cells assessed as reduction of virus-induced cytopathogenicity by MTT assay
    Antiviral activity against HIV1 with reverse transcriptase K103N/Y181C mutation in human MT4 cells assessed as reduction of virus-induced cytopathogenicity by MTT assay
    [PMID: 18226532]
    MT4 EC50
    0.013 μM
    Compound: EFV
    Antiviral activity against HIV-1 harboring NNTRI-resistant reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT method
    Antiviral activity against HIV-1 harboring NNTRI-resistant reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT method
    [PMID: 24933420]
    MT4 EC50
    0.015 μM
    Compound: Efavirenz
    Antiretroviral activity against Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    Antiretroviral activity against Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    [PMID: 18541726]
    MT4 EC50
    0.02 μM
    Compound: EFV
    Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathicity after 5 days by MTT assay
    Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathicity after 5 days by MTT assay
    [PMID: 23415090]
    MT4 EC50
    0.02 μM
    Compound: EFV
    Antiviral activity against HIV1 3B Y181C resistant mutant in human MT4 cells assessed as protection against viral induced cytopathogenicity by MTT assay
    Antiviral activity against HIV1 3B Y181C resistant mutant in human MT4 cells assessed as protection against viral induced cytopathogenicity by MTT assay
    [PMID: 18954921]
    MT4 EC50
    0.022 μM
    Compound: EFV
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of viral cytopathogenicity after 5 days by MTT assay
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of viral cytopathogenicity after 5 days by MTT assay
    [PMID: 24680058]
    MT4 IC50
    0.0226 μM
    Compound: EFV
    Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay
    Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay
    [PMID: 24952305]
    MT4 EC50
    0.025 μM
    Compound: Efavirenz
    Compound concentration required to achieve 50% protection of infected MT-4 cells from Y181C strain was determined by the MTT method
    Compound concentration required to achieve 50% protection of infected MT-4 cells from Y181C strain was determined by the MTT method
    [PMID: 15634015]
    MT4 EC50
    0.037 μM
    Compound: 2; EFV
    Antiviral activity against HIV1 harboring reverse transcriptase Y181C mutant infected in primary MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTS assay
    Antiviral activity against HIV1 harboring reverse transcriptase Y181C mutant infected in primary MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTS assay
    [PMID: 26804933]
    MT4 IC50
    0.04 μM
    Compound: Efavirenz
    Anti-HIV-1 activity against K103N strain in MT-4 cells by the MTT method
    Anti-HIV-1 activity against K103N strain in MT-4 cells by the MTT method
    [PMID: 14643315]
    MT4 IC50
    0.04 μM
    Compound: Efavirenz
    Anti-HIV-1 activity against K103N+Y181C strain was determined in MT-4 cells by the MTT method
    Anti-HIV-1 activity against K103N+Y181C strain was determined in MT-4 cells by the MTT method
    [PMID: 14643315]
    MT4 IC50
    0.04 μM
    Compound: Efavirenz
    Anti-HIV-1 activity against Y181C strain, in MT-4 cells by the MTT method
    Anti-HIV-1 activity against Y181C strain, in MT-4 cells by the MTT method
    [PMID: 14643315]
    MT4 EC50
    0.04 μM
    Compound: table 6,efavirenz
    Antiviral activity against HIV1 with reverse transcriptase K103N/Y181C mutation in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay
    Antiviral activity against HIV1 with reverse transcriptase K103N/Y181C mutation in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay
    [PMID: 18226533]
    MT4 EC50
    0.04 μM
    Compound: efavirenz
    Antiviral activity against HIV1 with reverse transcriptase Y181C mutation in human MT4 cells assessed as reduction of virus-induced cytopathogenicity by MTT assay
    Antiviral activity against HIV1 with reverse transcriptase Y181C mutation in human MT4 cells assessed as reduction of virus-induced cytopathogenicity by MTT assay
    [PMID: 18226532]
    MT4 EC50
    0.044 μM
    Compound: EFZ
    Antiviral activity against HIV1 isolates with reverse transcriptase Y181C mutation in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay
    Antiviral activity against HIV1 isolates with reverse transcriptase Y181C mutation in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay
    [PMID: 18630898]
    MT4 EC50
    0.049 μg/mL
    Compound: Efavirenz
    Antiviral activity against HIV 1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay
    Antiviral activity against HIV 1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay
    [PMID: 26385446]
    MT4 EC50
    0.054 μM
    Compound: EFV
    Antiviral activity against HIV-1 3B harboring RT L100I mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay
    Antiviral activity against HIV-1 3B harboring RT L100I mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay
    [PMID: 21872971]
    MT4 EC50
    0.057 μM
    Compound: Efavirenz
    Antiviral activity against HIV1 reverse transcriptase K103N mutant infected in human MT4 cells after 5 days by MTT assay
    Antiviral activity against HIV1 reverse transcriptase K103N mutant infected in human MT4 cells after 5 days by MTT assay
    [PMID: 19140683]
    MT4 EC50
    0.057 μM
    Compound: Efavirenz
    Antiviral activity against HIV1 K103N mutant in MT4 cells by MTT assay
    Antiviral activity against HIV1 K103N mutant in MT4 cells by MTT assay
    [PMID: 16621553]
    MT4 EC50
    0.057 μM
    Compound: EVZ
    Antiviral activity against HIV1 K103N mutant strain infected MT4 cells by MTT method
    Antiviral activity against HIV1 K103N mutant strain infected MT4 cells by MTT method
    [PMID: 16335924]
    MT4 EC50
    0.058 μM
    Compound: 2; EFV
    Antiviral activity against HIV1 harboring reverse transcriptase Y181C/K103N double mutant infected in primary MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTS assay
    Antiviral activity against HIV1 harboring reverse transcriptase Y181C/K103N double mutant infected in primary MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTS assay
    [PMID: 26804933]
    MT4 EC50
    0.06 μM
    Compound: EFV, DMP266, L-743,726
    Antiviral activity against 6-[(3,5-Dimethylphenyl)fluoromethyl]-5-ethyl-1-{[[4-(3-hydroxyprop-1-ynyl)benzyl]oxy]methyl}pyrimidine-2,4(1H,3H)-dione-resistant HIV1 harboring RT 106I, 181C mutant infected in human MT4 cells assessed as inhibition of virus-in
    Antiviral activity against 6-[(3,5-Dimethylphenyl)fluoromethyl]-5-ethyl-1-{[[4-(3-hydroxyprop-1-ynyl)benzyl]oxy]methyl}pyrimidine-2,4(1H,3H)-dione-resistant HIV1 harboring RT 106I, 181C mutant infected in human MT4 cells assessed as inhibition of virus-in
    [PMID: 24805780]
    MT4 EC50
    0.06 μM
    Compound: EFV
    Antiviral activity against NNRTI-resistant HIV1 A17 with reverse transcriptase K103N, Y181C mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay
    Antiviral activity against NNRTI-resistant HIV1 A17 with reverse transcriptase K103N, Y181C mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay
    [PMID: 19775780]
    MT4 EC50
    0.08 μM
    Compound: EFV, DMP266, L-743,726
    Antiviral activity against A17-sensitive HIV1 harboring 103N, 181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
    Antiviral activity against A17-sensitive HIV1 harboring 103N, 181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
    [PMID: 24805780]
    MT4 EC50
    0.08 μM
    Compound: EFV, efavirenz
    Antiviral activity against HIV1 with reverse transcriptase IRLL98 mutation in MT4 cells assessed as inhibition of viral induced cytopathic effect by MTT method
    Antiviral activity against HIV1 with reverse transcriptase IRLL98 mutation in MT4 cells assessed as inhibition of viral induced cytopathic effect by MTT method
    [PMID: 17910429]
    MT4 EC50
    0.086 μM
    Compound: Efavirenz
    Antiviral activity against non nucleoside reverse transcriptase inhibitor-resistant Human immunodeficiency virus 1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    Antiviral activity against non nucleoside reverse transcriptase inhibitor-resistant Human immunodeficiency virus 1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    [PMID: 18541726]
    MT4 EC50
    0.09 μM
    Compound: EFV, DMP266, L-743,726
    Antiviral activity against TMC120-resistant HIV1 harboring RT 100I, 138G mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
    Antiviral activity against TMC120-resistant HIV1 harboring RT 100I, 138G mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
    [PMID: 24805780]
    MT4 EC50
    0.09 μM
    Compound: EFV, efavirenz
    Antiviral activity against HIV1 with reverse transcriptase K103N mutation in MT4 cells assessed as inhibition of viral induced cytopathic effect by MTT method
    Antiviral activity against HIV1 with reverse transcriptase K103N mutation in MT4 cells assessed as inhibition of viral induced cytopathic effect by MTT method
    [PMID: 17910429]
    MT4 EC50
    0.1 μM
    Compound: EFV, DMP266, L-743,726
    Antiviral activity against MC1220-resistant HIV1 harboring RT 100I, 179D, 181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
    Antiviral activity against MC1220-resistant HIV1 harboring RT 100I, 179D, 181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
    [PMID: 24805780]
    MT4 EC50
    0.1 μM
    Compound: EFV
    Antiviral activity against HIV1 3B expressing reverse transcriptase L100I mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against HIV1 3B expressing reverse transcriptase L100I mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay
    [PMID: 26802545]
    MT4 EC50
    0.101 μM
    Compound: Efavirenz
    Inhibition of HIV-1 3B reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of viral replication after 5 days by cell titer glo based luciferase reporter gene assay
    Inhibition of HIV-1 3B reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of viral replication after 5 days by cell titer glo based luciferase reporter gene assay
    [PMID: 27371922]
    MT4 EC50
    0.108 μM
    Compound: EFV
    Antiviral activity against HIV-1 3B harboring RT K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay
    Antiviral activity against HIV-1 3B harboring RT K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay
    [PMID: 21872971]
    MT4 EC50
    0.11 μM
    Compound: EFV
    Antiviral activity against HIV1 with reverse transcriptase K103N, Y181C mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay
    Antiviral activity against HIV1 with reverse transcriptase K103N, Y181C mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay
    [PMID: 20598556]
    MT4 EC50
    0.12 μM
    Compound: EFV
    Antiviral activity against HIV1 3B expressing reverse transcriptase K103N mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against HIV1 3B expressing reverse transcriptase K103N mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay
    [PMID: 26802545]
    MT4 ED50
    0.133 μM
    Compound: EFV
    Antiviral activity against drug-resistant HIV1 with reverse transcriptase K103N mutant infected in human MT4 cells assessed as virus-induced cell death by MTT method
    Antiviral activity against drug-resistant HIV1 with reverse transcriptase K103N mutant infected in human MT4 cells assessed as virus-induced cell death by MTT method
    [PMID: 18842407]